港股異動 | 復鋭醫療科技(1696.HK)續升超6%再度破頂 年內股價大漲6.4倍
格隆匯5月18日丨醫美設備股復鋭醫療科技(1696.HK)繼續拉昇,現漲6.47%,盤中高見18.56港元再創歷史新高價,總市值超80億港元。該股今年迄今持續拉昇上揚,累計漲幅446%,股價大漲6.4倍。此前業績顯示,復鋭去年錄得少賺36%,毛利率增至55.7%。集團曾預期2021年上半年錄得的收益將較2020年同期錄得的收益大幅增長超過40%。此外,公司也進入了注射劑市場,並在以色列及中國香港均有銷售。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.